(1)

Etofenprox was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council (2) as an active substance for use in biocidal products of product-type 8 (wood preservatives). Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved under that Regulation subject to the requirements set out in Annex I to Directive 98/8/EC.

(2)

The approval of etofenprox for use in biocidal products of product-type 8 was to expire on 31 January 2020. On 27 July 2018, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of that approval.

(3)

Commission Implementing Decision (EU) 2019/994 (3) postponed the expiry date of the approval of etofenprox for use in biocidal products of product-type 8 to 31 October 2022, to allow sufficient time for the examination of the application for the renewal of that approval. Commission Implementing Decision (EU) 2022/1487 (4) postponed further the expiry date of the approval of etofenprox for use in biocidal products of product-type 8, to 31 October 2026, due to delays linked with the delivery of additional studies needed to assess the criteria for the determination of endocrine-disrupting properties of etofenprox.

(4)

Etofenprox was also approved as an active substance for use in biocidal products of product-type 18 by Commission Implementing Regulation (EU) No 1036/2013 (5) subject to the conditions set out in the Annex to that Regulation.

(5)

The approval of etofenprox for use in biocidal products of product-type 18 was to expire on 30 June 2025. On 25 October 2023, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of that approval.

(6)

Commission Implementing Decision (EU) 2025/434 (6) postponed the expiry date of the approval of etofenprox for use in biocidal products of product-type 18 to 31 December 2027, to allow sufficient time for the examination of the application for the renewal.

(7)

However, on 12 June 2025, the applicant who submitted the applications for the renewal of the approval of etofenprox for use in biocidal products for both product-types 8 and 18 informed the Commission that it withdrew its applications for the renewal of the approval.

(8)

Consequently, as it has not been established that etofenprox still meets the conditions laid down in Article 4(1) of Regulation (EU) No 528/2012, it is appropriate to not renew the approval.

(9)

In order to allow sufficient time for economic operators to adapt, treated articles treated with or incorporating etofenprox for use in biocidal products of product-types 8 and 18 may be placed on the market for a period of 180 days after the entry into force of this Decision.

(10)

The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Biocidal Products,